The results of the multicenter belatacept liver transplant trial disappoint with respect to safety and efficacy, and new approaches will be required before this agent plays a role in liver transplant immunosuppression. See article by Klintmalm et al on page 1817.
Bibliographical noteFunding Information:
The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. SJK is a stockholder of Bristol Myers Squibb. ABA receives grant money from Bristol Myers Squibb.